From the Chief Medical Officer
Dr Michael McBride

Circular HSC (SQSD) (NICE CG183) 23/14

Subject: NICE Clinical Guideline CG183 – Drug allergy: diagnosis and management of drug allergy in adults, children and young people

Circular Reference: HSC (SQSD) (NICE CG183) 23/14

Date of Issue: 17 October 2014

Related documents:
HSC (SQSD) 3/13

For information to:
Chair of HSC Board
Chair of Public Health Agency
Chairs of HSC Trusts
Chair of RQIA
NICE Implementation Facilitator NI
Members of NI NICE Managers’ Forum

Summary of Contents: This clinical guideline offers evidence-based advice on the diagnosis and management of drug allergy in adults, children and young people.

Enquiries:
Any enquiries about the content of this Circular should be addressed to:
Standards & Guidelines Quality Unit
DHSSPS
Room D1.4
Castle Buildings
Stormont Estate
BELFAST
BT4 3SQ

SGU-NICEGuidance@dhsspsni.gov.uk

Superseded documents
None

Status of Contents:
Action

Implementation:
As per circular. Generally, Clinical Guidelines should be implemented within 12 months of endorsement.

Additional copies:
Available to download from
http://www.dhsspsni.gov.uk/index/phealth/sqs/sqsd-guidance.htm
Dear Colleagues


The Department has recently reviewed the above NICE guidance and has formally endorsed it as applicable in Northern Ireland.

In accordance with the process outlined in circular HSC (SQSD) 3/13 (http://www.dhsspsni.gov.uk/hsc_sqsd__3_13.pdf), the following actions should be taken

1. HSC Board / PHA
   a. Identify a Professional Lead who will consider the commissioning implications of the Clinical Guideline and co-ordinate with any other relevant commissioning teams. This Lead will identify any areas where regional planning / investment / commissioning are required, or where there is material risk to safety or quality. These will then be actioned immediately through normal commissioning arrangements or through bespoke arrangements reflecting the nature of the issue / risk.
   b. Ensure that relevant guidance is sent to the appropriate Family Practitioners.
   c. Seek positive assurance from the HSC Trusts that the required initial actions have been undertaken within a 3 month period, and that the Guideline has been implemented within a further 9 months (unless otherwise notified by the HSC Trusts).
   d. Where significant investment/ commissioning needs cannot be met within the usual timeframe, agree appropriate arrangements with HSC Trusts. Report to DHSSPS as required at 6 monthly accountability meetings.

2. HSC Trusts
   a. Proceed with targeted dissemination, agree a clinical/management lead to coordinate implementation and consider what has to be done to achieve implementation using a risk based assessment and baseline review as appropriate to support planning. These initial actions should be undertaken within a three month period.
   b. Implement the Guideline within a further 9 months (apart from any elements where significant issues have been raised with the HSC Board/PHA).
   c. Provide positive assurances to the HSC Board that required initial actions have been taken within the 3 month planning period and that the Guideline has been implemented within a further 9 months, where appropriate.
   d. Where significant investment/ commissioning needs cannot be met within the usual timeframe, notify the HSC Board/PHA at the earliest opportunity through the bi-monthly director level meetings and agree appropriate arrangements with them to achieve implementation.

3. RQIA
   a. Disseminate the Guideline to the independent sector as appropriate.

4. HSC Special Agencies and NDPBs
   a. Take account of this Guideline in training and other developments as appropriate.
To inform the planning process, please find attached details from the Departmental review including estimates of costs / savings based on the NICE costing template, where this is applicable. You should also consider and take account of other relevant Departmental policies and strategies in your planning, as well as any legislative / policy caveats identified in the course of the Departmental review.

A full current list of NICE guidance endorsed for application in Northern Ireland can be found on the Department’s website (http://www.dhsspsni.gov.uk/index/phealth/sqs/sqsd-guidance/sqsd-guidance-nice-guidance.htm).

Dr Michael McBride
Chief Medical Officer
**Appendix 1**

### Endorsed NICE guidance - Details from Departmental review

<table>
<thead>
<tr>
<th>Reference Number</th>
<th>NICE Clinical Guideline - CG183</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Title</strong></td>
<td>Drug allergy: diagnosis and management of drug allergy in adults, children and young people</td>
</tr>
<tr>
<td><strong>Summary of guidance</strong></td>
<td>This clinical guideline (published by NICE in September 2014) offers evidence-based advice on the diagnosis and management of drug allergy in adults, children and young people.</td>
</tr>
<tr>
<td><strong>Number of people expected to take up or benefit from the service / therapy</strong></td>
<td>Unable to calculate for Northern Ireland.</td>
</tr>
<tr>
<td><strong>Costs / savings associated with implementation</strong></td>
<td>Due to wide variation in current practice the cost of fully implementing this guidance in Northern Ireland cannot be estimated with any degree of certainty. There may be increased costs associated with referrals which are low cost, however, these could be offset by improved quality of care to patients and substantial short-term and longer-term resource benefits to HSC.</td>
</tr>
<tr>
<td><strong>Related strategically relevant DHSSPS policies</strong></td>
<td>None</td>
</tr>
<tr>
<td><strong>Inter-Departmental interest</strong></td>
<td>None</td>
</tr>
<tr>
<td><strong>Legislative / policy caveats</strong></td>
<td>This advice does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case. The Mental Capacity Act 2005 and the Department of Health document ‘Reference Guide to Consent for Treatment or Examination’ do not apply in NI, but work is under way to bring forward similar legislation for NI, incorporating mental capacity and mental health provisions. The DHSSPS guidance</td>
</tr>
</tbody>
</table>
‘Reference Guide to Consent for Examination, Treatment or Care (2003)’, which is available on the DHSSPS website, gives advice on determining whether a person has capacity and on what action may be taken where the person lacks capacity. Available from: http://www.dhsspsni.gov.uk/consent-referenceguide.pdf

The Department of Health guidance ‘Transition: getting it right for young people’ does not apply in Northern Ireland. Provision of appropriate transition care for young people as they move from paediatric to adolescent and adult care will be taken forward in the Department’s planned review of paediatric services.